Pharmacokinetic evaluation of roflumilast

Accessory Cardiac Bronchus

(2011) Eric S. White   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Roflumilast with long-acting  2-agonists for COPD: influence of exacerbation history

(2011) E. D. Bateman et al.   EUROPEAN RESPIRATORY JOURNAL

Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects

(2011) Andreas Huennemeyer et al.   Expert Opinion On Drug Safety

Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide

(2011) G. Lahu et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study

(2011) T.D. Bethke et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects

(2011) N. McCracken et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults

(2011) G. Böhmer et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model

(2010) Gezim Lahu et al.   CLINICAL PHARMACOKINETICS

Effect of Steady-State Enoxacin on Single-Dose Pharmacokinetics of Roflumilast and Roflumilast N-Oxide

(2010) Gezim Lahu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

No Dose Adjustment on Coadministration of the PDE4 Inhibitor Roflumilast With a Weak CYP3A, CYP1A2, and CYP2C19 Inhibitor: An Investigation Using Cimetidine

(2010) Gabriele M. Böhmer et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

(2010) John R. Hurst et al.   NEW ENGLAND JOURNAL OF MEDICINE

The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

(2010) Armin Hatzelmann et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects

(2009) Nassr Nassr et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Targeted Oral, Once-Daily Phosphodiesterase 4 Inhibitor Roflumilast and the Leukotriene Receptor Antagonist Montelukast Do Not Exhibit Significant Pharmacokinetic Interactions

(2009) Gabriele M. Böhmer et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

(2009) Leonardo M Fabbri et al.   LANCET

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

(2009) Peter MA Calverley et al.   LANCET

Emerging Pharmacotherapies for COPD

(2008) Peter J. Barnes   CHEST

Update on the Management of COPD

(2008) Bartolome R. Celli   CHEST

Effect of Single and Repeated Doses of Ketoconazole on the Pharmacokinetics of Roflumilast and Roflumilast N-Oxide

(2008) Gezim Lahu et al.   JOURNAL OF CLINICAL PHARMACOLOGY